Biosimilars

Business & Regulation Biosimilars

A New Supporter

05/09/2018 | Stephanie Vine

Initially, The American College of Rheumatology was cautious about biosimilars, but times have changed.

Discovery & Development Biosimilars

What Regulators Want

05/09/2018 | Bruno Speder

The path to market for a biosimilar involves an abbreviated approval process, focused on proving “biosimilarity”.

Discovery & Development Biosimilars

I’m a (Biosimilars) Believer!

05/09/2018 | Stephanie Vine

Why does the full potential of biosimilars remain untapped? Four experts weigh in.

Business & Regulation Biosimilars

Business in Brief

05/09/2018 | Stephanie Vine

The latest business news and views in pharma.

Manufacture Biosimilars

Open Your Mind

05/09/2018 | Roisin McGuigan

Why is the pharma industry overly reluctant to accept new ideas?

Manufacture Standards & Regulation

Raising the Biosimilar Banner

03/14/2018 | Stephanie Vine

FDA Commissioner Scott Gottlieb wants more biosimilars on the US market.

Business & Regulation Biosimilars

Breaking Barriers to Biosimilars

12/13/2017 | James Strachan

Sitting Down With… Richard Markus, Vice President of Global Development, Amgen, USA

Business & Regulation Biosimilars

Business-in-Brief

11/22/2017 | William Aryitey

EMA relocation, a price-fixing scandal, and FDA warning letters… What's new for pharma in business?

Discovery & Development Biosimilars

Champion of Generics

09/20/2017 | Abhijit Mukherjee

Sitting Down With… Abhijit Mukherjee, COO of Dr. Reddy's Laboratories, India

Discovery & Development Biosimilars

Being (Bio)Better

08/07/2017 | Darrell Sleep

Why stop at biosimilar when you can be biobetter?

2
3
4
5
6
...

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

Unlimited access to ALL articles
News, interviews & opinions from leading industry experts
Receive print (and PDF) copies of The Medicine Maker magazine